Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


 
SGX Initiates Phase I Trials for SGX523 for Breast, Colon, Prostate
By Dross at 2008-01-17 02:02
SGX Initiates Phase I Trials for SGX523 for Breast, Colon, Prostate

SGX Pharmaceuticals, Inc. (NASDAQ:SGXP) today announced that it has opened enrollment in two Phase I studies, with the first patient being treated on January 14, 2008. The Phase I studies are designed to evaluate the safety, tolerability and pharmacokinetic profile of SGX523, an internally developed, orally-bioavailable, small molecule inhibitor of the cMET receptor tyrosine kinase.

The Phase I clinical trials are open-label, dose escalation studies of SGX523 administered orally to patients with advanced cancer who have either failed standard therapy or for whom no standard therapy exists. The studies are designed to explore two dosing regimens in parallel. The continuous dosing trial will have continuous uninterrupted twice daily dosing with patients being evaluated every 28 days for continuation of treatment. The intermittent dosing schedule will implement twice daily dosing on a 14 days on/7 days off therapy schedule, cycling every 21 days. In both protocols, patients may continue on therapy for up to 12 months as determined by the patient's response and tolerance to SGX523.

"SGX523 is our first internally discovered clinical candidate. We are excited to begin studying SGX523 in humans and to achieve the first of our 2008 clinical development goals," said Mike Grey, President and Chief Executive Officer of SGX Pharmaceuticals. "With two separate dosing schedules, we believe that we will be able to collect important data that could serve as a basis for future clinical development activities and position us to capitalize on the evolving cMET opportunity."



2350 reads

 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate





All times are GMT -5. The time now is 04:51 PM.